LARIMAR THERAPEUTICS, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
LARIMAR THERAPEUTICS, INC. (LRMR) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2023-05-15
- LARIMAR THERAPEUTICS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-03-31 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month |
|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |